OPTIMI HEALTH CORP - OPTHF STOCK NEWS

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN), a GMP-compliant, Health Canada-licensed manufacturer of psychedelics specializing in botanical psilocybin and MDMA, has announced a leadership transition. Mr. William (Bill) Ciprick is stepping down as Chief Executive Officer due to personal reasons after three years of leading the company.

The Board of Directors has appointed Mr. Dane Stevens, Co-Founder of Optimi, as Interim Chief Executive Officer, effective immediately. Mr. Stevens will focus on advancing key initiatives, including business development, expanding revenue opportunities, and maintaining the company's strategic direction. Mr. Ciprick will continue to support the company in an advisory capacity during this transition period.

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) has received a No Objection Letter from Health Canada for a Phase 2 clinical trial using their GMP natural psilocybin extract capsules. The trial, conducted with ATMA Journey Centers, will study Major Depressive Disorder in 200 frontline mental healthcare workers affected by COVID-19. This approval marks a significant step in Optimi's clinical validation efforts in Canada, complementing their ongoing Real World Evidence collection in Australia.

The study aims to assess the safety, efficacy, and therapeutic potential of psilocybin-assisted psychotherapy. It will also explore how psilocybin might enhance the professional capacities of healthcare workers, particularly in psychedelic therapy. This research could provide important insights into new treatment options for those most affected by the pandemic's mental health challenges.

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) has achieved several significant milestones:

• Completed the first export of GMP-validated MDMA capsules to Australia for PTSD treatment under the Authorised Prescriber Scheme
• Received permits for psilocybin shipment to New Zealand for a pilot study
• Influenced Australian regulatory framework for MDMA and psilocybin manufacturing requirements
• Closed the first tranche of a non-brokered private placement, raising CAD$538,999.80

These developments position Optimi as a leader in the psychedelics pharmaceutical industry, with a focus on MDMA and psilocybin for mental health treatments.

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer, has announced a non-brokered private placement of up to 16,666,666 units at CAD$0.30 per unit, aiming to raise up to CAD$5,000,000. Each unit consists of one common share and half a warrant, with each full warrant allowing the purchase of an additional share at CAD$0.40 for two years.

The company plans to use the proceeds for business development in Australia and globally, commissioning new equipment for GMP production and analytical laboratory, and general working capital. Insiders may participate for up to CAD$500,000. The offering includes an accelerated expiry provision and a potential 4% finder's fee for qualified non-related parties.

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) has announced a strategic partnership with PsiloThai, marking its entry into the Asian medical market for psilocybin research. This collaboration follows Thailand's recent regulatory change permitting psilocybin for medical treatment and research. Optimi will supply its GMP-approved natural psilocybin extract capsules for observational studies focusing on patients with addiction and end-of-life distress.

The studies will be conducted in conjunction with Government Hospitals and Rajamangala University, pending formal approval from Thai health authorities. This partnership not only expands Optimi's global footprint but also aligns with Thailand's progressive stance on psychedelic research, potentially paving the way for broader acceptance in Asia.

Optimi Health has announced the launch of OptiMed, an online portal aimed at assisting Australian psychiatrists in prescribing psychedelic medicines like psilocybin and MDMA. Developed in collaboration with Mind Medicine Australia, the portal offers a centralized, secure hub for essential information, resources, and support related to psychedelic drug manufacturing and training. The platform ensures compliance with Australia's Authorised Prescriber Scheme, providing insights into Good Manufacturing Practices (GMP) and facilitating secure communication.

The user-friendly interface allows psychiatrists to easily access comprehensive resources, including multimedia content showcasing Optimi's GMP-compliant facility. Currently, OptiMed is available solely to Australian psychiatrists, with plans for future international expansion. Psychiatrists can register for access through the portal's website.

Optimi Health has received three export permits from Health Canada to supply MDMA and psilocybin capsules to Australian psychiatrists for treating PTSD and Treatment-Resistant Depression. With a shipment of 160 doses, this marks the company's first commercial entry into Australia. The capsules will be used under the Authorised Prescriber Scheme, facilitated by Mind Medicine Australia. This initiative aims to gather Real World Evidence and Patient-Reported Outcomes to support the therapeutic potential of these substances. Optimi's export is made possible by its GMP-compliant production facility and newly awarded Drug Establishment Licence.

Optimi Health has completed its first international shipment of MDMA to Israel's Institute for Psychedelic Research at Tel Aviv University, facilitated by an export permit from Health Canada. This marks a significant milestone for Optimi, emphasizing its ability to manufacture and export controlled substances globally. Additionally, Optimi has received the CERS and CBSA Exporters Authorization ID, ensuring compliance with international trade regulations.

Optimi has also engaged Oak Hill Financial for investor relations, aiming to enhance communication with potential investors. Recent achievements include obtaining a Drug Establishment Licence from Health Canada, enabling production and distribution of MDMA and psilocybin capsules. Optimi can now supply GMP-compliant psychedelic drug solutions from its Princeton, BC facility for global distribution.

Optimi Health has been granted a Drug Establishment Licence (DEL) from Health Canada, allowing the company to manufacture and sell MDMA and psilocybin capsules. This accreditation confirms their compliance with Good Manufacturing Practices (GMP) and enables the global distribution of these drugs, pending export documentation. Optimi plans to register these drugs with the U.S. FDA through Mutual Recognition Agreements (MRAs). The company will provide 160 doses to Australia under the Therapeutic Goods Administration's Authorized Prescriber Scheme. This milestone is expected to enhance Optimi's position in the global psychedelics market, offering comprehensive GMP psychedelic drug solutions for manufacturing, export, and distribution.